JP6482274B2 - 皮膚バリア機能を改善するのに有用なホホバ抽出物 - Google Patents
皮膚バリア機能を改善するのに有用なホホバ抽出物 Download PDFInfo
- Publication number
- JP6482274B2 JP6482274B2 JP2014544045A JP2014544045A JP6482274B2 JP 6482274 B2 JP6482274 B2 JP 6482274B2 JP 2014544045 A JP2014544045 A JP 2014544045A JP 2014544045 A JP2014544045 A JP 2014544045A JP 6482274 B2 JP6482274 B2 JP 6482274B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition
- jojoba
- extract
- barrier function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 97
- 235000004433 Simmondsia californica Nutrition 0.000 title claims description 80
- 230000008591 skin barrier function Effects 0.000 title claims description 39
- 241000221096 Simmondsia chinensis Species 0.000 title 1
- 210000003491 skin Anatomy 0.000 claims description 103
- 239000000203 mixture Substances 0.000 claims description 82
- 241000196324 Embryophyta Species 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 40
- 239000002798 polar solvent Substances 0.000 claims description 24
- 230000001737 promoting effect Effects 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- 230000004888 barrier function Effects 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 206010021198 ichthyosis Diseases 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 230000036559 skin health Effects 0.000 claims description 7
- 230000037067 skin hydration Effects 0.000 claims description 7
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000037075 skin appearance Effects 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000003167 cholangitis Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940113120 dipropylene glycol Drugs 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 229940051250 hexylene glycol Drugs 0.000 claims description 3
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 230000037311 normal skin Effects 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 239000004029 environmental poison Substances 0.000 claims description 2
- 230000036074 healthy skin Effects 0.000 claims description 2
- 230000013632 homeostatic process Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 241000221095 Simmondsia Species 0.000 claims 7
- 230000032683 aging Effects 0.000 claims 1
- 230000037393 skin firmness Effects 0.000 claims 1
- 244000044822 Simmondsia californica Species 0.000 description 77
- 108090000623 proteins and genes Proteins 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 30
- 238000012360 testing method Methods 0.000 description 24
- 239000000463 material Substances 0.000 description 22
- 238000000605 extraction Methods 0.000 description 21
- 239000010410 layer Substances 0.000 description 20
- 108010076876 Keratins Proteins 0.000 description 19
- 102000011782 Keratins Human genes 0.000 description 18
- 210000000434 stratum corneum Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 102000029792 Desmoplakin Human genes 0.000 description 15
- 108091000074 Desmoplakin Proteins 0.000 description 15
- 210000002615 epidermis Anatomy 0.000 description 15
- 210000002510 keratinocyte Anatomy 0.000 description 15
- 108010067306 Fibronectins Proteins 0.000 description 13
- 102000016359 Fibronectins Human genes 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 102100035721 Syndecan-1 Human genes 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000036571 hydration Effects 0.000 description 9
- 238000006703 hydration reaction Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 8
- 108010070553 Keratin-5 Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 210000003963 intermediate filament Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 108090000058 Syndecan-1 Proteins 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- -1 ny Species 0.000 description 7
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000001047 desmosome Anatomy 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 108010033564 involucrin Proteins 0.000 description 6
- 102000007236 involucrin Human genes 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 6
- 210000001578 tight junction Anatomy 0.000 description 6
- 102100022854 Keratin, type II cytoskeletal 2 epidermal Human genes 0.000 description 5
- 108010065038 Keratin-10 Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 101710194922 Keratin, type II cytoskeletal 1 Proteins 0.000 description 4
- 108010070520 Keratin-2 Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 108060008539 Transglutaminase Proteins 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 239000012911 assay medium Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004292 cytoskeleton Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940119170 jojoba wax Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000003601 transglutaminase Human genes 0.000 description 4
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 108010070514 Keratin-1 Proteins 0.000 description 3
- 102000005714 Keratin-2 Human genes 0.000 description 3
- 102000030412 Plakin Human genes 0.000 description 3
- 108091000120 Plakin Proteins 0.000 description 3
- 108050006774 Syndecan Proteins 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- VGPYEHKOIGNJKV-UHFFFAOYSA-N asulam Chemical compound COC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VGPYEHKOIGNJKV-UHFFFAOYSA-N 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 210000003976 gap junction Anatomy 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 101000975494 Bos taurus Keratin, type II cytoskeletal 8 Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 102100038199 Desmoplakin Human genes 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 2
- 101001046936 Homo sapiens Keratin, type II cytoskeletal 2 epidermal Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 101710145498 Keratin, type II cytoskeletal 2 epidermal Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 244000237986 Melia azadirachta Species 0.000 description 2
- 235000013500 Melia azadirachta Nutrition 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 108010019965 Spectrin Proteins 0.000 description 2
- 102000005890 Spectrin Human genes 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 108090000054 Syndecan-2 Proteins 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960005193 avobenzone Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000008619 cell matrix interaction Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical compound CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000013636 protein dimer Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 229940013123 stannous chloride Drugs 0.000 description 2
- 239000010698 whale oil Substances 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- 101710152719 60S ribosomal protein L13a Proteins 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 101001125931 Arabidopsis thaliana Plastidial pyruvate kinase 2 Proteins 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 235000007601 Carya glabra Nutrition 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102000004162 Claudin-1 Human genes 0.000 description 1
- 108090000600 Claudin-1 Proteins 0.000 description 1
- 235000003697 Conopodium majus Nutrition 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102000005708 Desmoglein 1 Human genes 0.000 description 1
- 108010045579 Desmoglein 1 Proteins 0.000 description 1
- 101150101992 Dsp gene Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 241000221785 Erysiphales Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108700041153 Filaggrin Proteins Proteins 0.000 description 1
- 241001284615 Frangula californica Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000883444 Homo sapiens Desmoplakin Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101100341652 Homo sapiens KRT2 gene Proteins 0.000 description 1
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
- 101001046960 Homo sapiens Keratin, type II cytoskeletal 1 Proteins 0.000 description 1
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 1
- 101000629361 Homo sapiens Paraplegin Proteins 0.000 description 1
- 101001125939 Homo sapiens Plakophilin-1 Proteins 0.000 description 1
- 101000583179 Homo sapiens Plakophilin-2 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 235000004185 Hyptis suaveolens Nutrition 0.000 description 1
- 101150027725 IVL gene Proteins 0.000 description 1
- 101150058971 KRT10 gene Proteins 0.000 description 1
- 101150037996 KRT5 gene Proteins 0.000 description 1
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- 238000003222 MTT reduction assay Methods 0.000 description 1
- 101000870233 Manduca sexta Diuretic hormone 2 Proteins 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019944 Olestra Nutrition 0.000 description 1
- 102100027006 Paraplegin Human genes 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241001343012 Piptadenia Species 0.000 description 1
- 102100029331 Plakophilin-1 Human genes 0.000 description 1
- 102100030348 Plakophilin-2 Human genes 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 102100029796 Protein S100-A10 Human genes 0.000 description 1
- 101710110950 Protein S100-A10 Proteins 0.000 description 1
- 102100032421 Protein S100-A6 Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
- 101150002135 SDC1 gene Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 241001530126 Scrophularia Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 241001111950 Sonora Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000003705 Syndecan-1 Human genes 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940075946 dermatop Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000012624 non-invasive in vivo measurement Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000032954 positive regulation of cell adhesion Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 102000042996 syndecan proteoglycan family Human genes 0.000 description 1
- 108091077880 syndecan proteoglycan family Proteins 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Description
(a) ホホバ植物またはその任意の部分を少なくとも1つの極性溶媒と混合するステップ;
(b) 液体抽出物を生成するのに十分な時間、前記混合物をインキュベートするステップ;
(c) ホホバ植物またはその部分を除去し、前記液体抽出物を収集するステップ;
(d) 前記液体抽出物を濾過するステップ;そして
(e) 前記濾液を収集するステップ
を包含する方法により製造されるホホバ抽出物を含む。
(a) ホホバ植物またはその任意の部分を少なくとも1つの極性溶媒と混合するステップ;
(b) 液体抽出物を生成するのに十分な時間、前記混合物をインキュベートするステップ;
(c) ホホバ植物またはその部分を除去し、前記液体抽出物を収集するステップ;
(d) 前記液体抽出物を濾過するステップ;そして
(e) 前記濾液を収集するステップ
により産生される抽出物を含む組成物を提供する。
実施例1: ホホバ抽出物の製造
生き生きした、汚染されていないホホバ植物は、暗緑色〜褐色を有する。したがって、抽出のために採取された植物部分を、それらの色に関して検査した。斑点、特に白色斑点を示す明黄色の葉または植物部分を除去した。次に、植物部分を、部分的にまたは完全に乾燥させた。乾燥植物部分を、1:2〜1:5の比率で、典型的には1:2の比率(植物部分:水)で、室温で水に付加した。混合物を100℃で2時間の間加熱して、一晩放置冷却した。4500rpmで30分間、遠心分離(Sigma Laborzentrifugen 3−10 3645 g)により固体を除去した。上清を収集し、1.2ミクロンフィルターを通して、次いで0.45ミクロンフィルターを通して、最後に0.22ミクロンフィルターを通して濾過し、濾液を収集した。濾液に、1%アスコルビン酸、1%および50%グリセリンを付加して、最終組成物を生成した。
0.03%でホホバ抽出物を用いて、cDNAアレイ遺伝子発現試験を実施した(hBA15m−NHEK バッチ15/10/07、1:2の葉:水比率で、本明細書中の実施例1に上記したように調製;フェノール含量 7617.7mg/L 没食子酸当量;トロロックス当量 108.6mM;防腐剤付加せず)。供給源抽出物の希釈を、検定媒質(下記参照)を用いて実行した。
細胞型: 正常ヒト表皮ケラチノサイト(NHEK)
K074(第3継代で使用)
培養条件: 37℃、5%CO2
培地: ケラチノサイト−SFM(Invitrogen17005−034);表皮増殖因子(EGF)0.25ng/ml、下垂体抽出物(PE)25μg/ml(Invitrogen3700015)、ゲンタマイシン25μg/ml(Sigma G1397)を補足。
検定培地: ケラチノサイト−SFM(Invitrogen17005−034);ゲンタマイシン25μg/ml(Sigma G1397)を補足。
プレートフォーマット: 96ウェル
細胞/ウェル: 20000NHEK、ケラチノサイト−SFM−EGF−PE培地
複製: 6
濃度範囲: 表2参照
細胞/化合物接触: 24時間
評価パラメーター: MTT還元検定および顕微鏡(対物×10)による形態学的観察
正常ヒト表皮ケラチノサイト(NHEK)細胞を、集密になるまで培地中で12ウェルプレート中に播種し、次いで、検定培地中でプレート化した。次に、ホホバ抽出物を試験ウェルに付加し、37℃で5%CO2で24時間、細胞を培養した。検定培地単独中で培養した細胞を、対照として用いた。各条件(試験/対照)を、n=3で実施した。
遺伝子発現の試験用に提供され、スクリーニング目的のために特定的に適合される標準ミニチップを用いて、遺伝子発現の解析を実施した(BIOalternatives(フランス)製造)。
逆転写
供給元の助言に従ってTri−reagentを用いて、各試料から総RNAを抽出した。
無DNA系(Ambion ref 1906)を用いて、DNAの潜在的汚染痕跡を除去した。
オリゴ(dT)およびSuperscript II逆転写酵素(Invitrogen)の存在下で、mRNAの逆転写をおこなった。
供給元推奨のプロトコールに従って、ライトサイクラー(LightCycler)(登録商標)系(Roche Molecular Systems Inc.)を用いて、三重反復試験でPCR反応を実施した。この系は、試験プライマーの解析条件を確定後、迅速かつ強力なPCR反応を可能にする。それは、以下の2つの構成成分からなる:
サーモサイクラー:迅速PCR適用のために最適化される;反応混合物内の非常に迅速な熱伝導を可能にする。
蛍光光度計: インターカレート染料SYBRグリーンIの定常蛍光測定を可能にする;伸長周期中に二本鎖DNAと特異的に結合する染料(検出波長:521nm)。
増幅DNA中への蛍光染料の組み入れを、PCR周期中、継続的に測定した。結果を、「蛍光強度」対「PCR周期」プロットとして描いて、各マーカーに関する相対発現(RE)値の評価を可能にした。
(1/2周期数)×106
マイクロソフト・エクセル(登録商標)ソフトウェアで、生データを解析した。
平均の標準誤差(sem)を以下のように算定した:平均=Sd/√n。
生存度のパーセンテージ(%)を、以下のように測定した:
(OD試料/OD対照)×100
すべての試験遺伝子を伴うミニチップ設計は、本明細書中の上記の表1に示されている。図1は、0.03%ホホバ抽出物で24時間処理されたケラチノサイト(図1B)と比較した場合の対照ケラチノサイト(図1A)における試験遺伝子の発現を示す。
サイトケラチン5(K5;CK5)、II型細胞骨格5ケラチン(KRT5)とも呼ばれる;58kDaサイトケラチン:229%相対発現(=刺激);
デスモプラキンIおよびII(DSP;DPIおよびDPII):185%相対発現(=中等度刺激);
サイトケラチン2E/A(K2E;CK2E)、II型細胞骨格2表皮ケラチン(KRT2E;KRT2A);(ジーメンスの表皮性魚鱗癬水疱症):160%相対発現(=中等度刺激);
サイトケラチン1(K1;CK1)、II型細胞骨格11ケラチン(KRT11)とも呼ばれる;67kDa サイトケラチン;毛アルファタンパク質:156%相対発現(=中等度刺激);
シンデカン−1(SYND1;SDC1)、CD138抗原とも呼ばれる:160%相対発現(=中等度刺激);
細胞マトリクス接着調節因子(CMAR;CAR):146%相対発現(=中等度刺激);
サイトケラチン10(K10)、I型細胞骨格10ケラチンとも呼ばれる:146%相対発現(=中等度刺激);
インボルクリン:154%相対発現(=中等度刺激);
フィブロネクチン(FN):146%相対発現(=中等度刺激)。
48時間の閉塞パッチ下で、健常成人有志の背部皮膚への抽出物の単一回適用により、ホホバ抽出物に対する皮膚耐容性を測定した。
11名の健常女性有志(年齢43〜67歳)に関して、二重盲検検定で経皮水分損失(TEWL)を検査した。初回適用(D0)前、ならびにTewameter(登録商標)(Courage & Khazaka)を用いた適用の28日後(D28)に、有志の前腕でTEWLを測定した。各前腕で2回の測定を行って、平均を算定した。TEWL変動(パーセンテージ)を、D0とD28の間で算定した。TEWLの減少は、皮膚バリア機能の改善を表す。
デルマトップ(登録商標)(EOTECH−フランス)を用いて、in vivoでの皮膚軽減パラメーターを調べることにより、ホホバ抽出物のアンチエイジング作用を査定した。皮膚軽減パラメーターは、平均の肌理の粗さ(Ra);最大振幅(Rt);および平均軽減(Rz)を包含した。
(1)Ra:平均の肌理の粗さ(μm):このパラメーターの減少は平滑作用を特徴づける;(2)Rz:平均軽減(μm):すべてのpicks対谷高の平均;(3)軽減振幅(μm):5つの最大picks対谷高の平均。
平均で−2.1μmという平均の肌理の粗さの有意の減少、すなわち−6%;
65%の被験者に観察された平滑作用;
平均で−8.6μmという平均軽減(Rz)の有意の減少、すなわち−8%;
平均で−18.0μmという軽減増幅(Rt)の有意の減少、すなわち−9%;ならびに
65%〜73%の被験者で観察されたテンソル作用。
角質層粘着性に及ぼすホホバ抽出物(本明細書中の上記の実施例5に記載されたIBRGapture(登録商標))の作用を、前腕からD−Squam(登録商標)で取り出された皮膚試料の分析により評価する。D−Squam(登録商標)の適用中に加えられる圧力は、QDerm(登録商標)を用いて制御される。
Claims (20)
- 皮膚の構造、強度、粘着性またはその任意の組合せを保持するか、および/または促進し、それにより皮膚バリア機能を保持するかまたは促進するための組成物であって、極性溶媒中のホホバ(Simmondsia chinensis)植物またはその部分の抽出物を活性成分として含み、前記組成物が隣接する表皮ケラチノサイト間を密に連結するためのものであり、
前記抽出物が、前記ホホバ植物またはその部分を極性溶媒中で60℃〜120℃の範囲の温度でインキュベートすることによって抽出される、組成物。 - 皮膚バリア機能を保持するかまたは促進することが、皮膚脱水率を保持するかまたは低減すること;皮膚水和値を保持するかまたは促進すること;環境害毒からの防御を保持するかまたは促進すること、ならびにその任意の組合せのうちの少なくとも1つを包含する請求項1記載の組成物。
- 皮膚の健康、皮膚の完全性、皮膚の引き締まり、皮膚の伸展性、皮膚の弾性、全体的皮膚外見およびその任意の組合せを保持することまたは改善することのうちの少なくとも1つにおいて有効である請求項1記載の組成物。
- 皮膚の健康を改善することが、湿疹、皮膚疾患、尋常性乾癬、扁平苔癬、魚鱗癬、尋常性魚鱗癬および胆道炎の症候を軽減すること;水疱症を防止すること;正常皮膚恒常性を保持すること;皮膚創傷治癒を助長することおよびその任意の組合せのうちの少なくとも1つを包含する請求項3記載の組成物。
- 全体的皮膚外見を促進することが、皺および線を含めた加齢および風化皮膚の可視的徴候を防止すること;皮膚表面を平坦にすること;皮膚孔サイズを低減することまたはその任意の組合せのうちの少なくとも1つを包含する請求項3記載の組成物。
- 前記皮膚の構造、強度、粘着性またはバリア機能を促進することまたは保持することが、予定閾値と比較して決定される請求項1記載の組成物。
- 前記予定閾値が、皮膚への組成物の投与前に測定される値である請求項6記載の組成物。
- 前記予定閾値が、健常皮膚を有する個体から得られる平均値である請求項6記載の組成物。
- 前記予定閾値が、肌荒れを有する個体から得られる平均値である請求項6記載の組成物。
- 前記極性溶媒が、水、エタノール、プロピレングリコール、ブチレングリコール、メタノール、グリセロール、プロパノール、ブタノール、ジプロピレングリコール、ペンチレングリコール、へキシレングリコール、ジメチルホルムアミド、アセトニトリル、ジメチルスルホキシド、ジクロロメタン、酢酸エチル、テトラヒドロフラン、蟻酸、酢酸、アセトンおよびその任意の組合せからなる群から選択される請求項1記載の組成物。
- 前記極性溶媒が水である請求項10記載の組成物。
- 前記極性溶媒が水、ならびにエタノール、プロピレングリコール、ブチレングリコール、メタノール、グリセロールおよびアセトンのうちの少なくとも1つである請求項10記載の組成物。
- 前記組成物が、化粧上または製薬上許容可能な希釈剤、担体または賦形剤をさらに含む化粧用または薬学的組成物である請求項1記載の組成物。
- 前記化粧用または薬学的組成物が局所適用のために処方される請求項13記載の組成物。
- 前記組成物が、少なくとも1つの付加的活性成分をさらに含む請求項1記載の組成物。
- 皮膚の構造、強度、粘着性またはその任意の組合せを保持するか、および/または促進し、それにより皮膚バリア機能を保持するかまたは促進するための組成物であって、極性溶媒中のホホバ(Simmondsia chinensis)植物またはその部分の抽出物を活性成分として含み、前記組成物が隣接する表皮ケラチノサイト間を密に連結するためのものであり、
前記抽出物が以下の:
a. ホホバ植物またはその任意の部分を少なくとも1つの極性溶媒と混合するステップ;
b. 液体抽出物を生成するのに十分な時間、前記混合物をインキュベートするステップ;
c. ホホバ植物またはその部分を取り出し、前記液体抽出物を収集するステップ;
d. 前記液体抽出物を濾過するステップ;そして
e. 前記濾液を収集するステップ
を包含する方法により製造され、
前記インキュベーション温度が60℃〜120℃の範囲である、組成物。 - ステップ(e)の前記濾液が、1.5μ未満の孔サイズを有するフィルターを通してさらに濾過される請求項16記載の組成物。
- 前記ホホバ植物部分が、根、茎、葉、種子、果実またはその任意の組合せからなる群から選択される請求項16記載の組成物。
- 前記植物部分が葉である請求項16記載の組成物。
- 前記ホホバ植物またはその部分が、新鮮、部分的乾燥または完全乾燥形態からなる群から選択される形態である請求項16記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564886P | 2011-11-30 | 2011-11-30 | |
US61/564,886 | 2011-11-30 | ||
PCT/IL2012/050484 WO2013080205A1 (en) | 2011-11-30 | 2012-11-28 | Jojoba extract useful in improving skin barrier functions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017181977A Division JP2018027965A (ja) | 2011-11-30 | 2017-09-22 | 皮膚バリア機能を改善するのに有用なホホバ抽出物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015502942A JP2015502942A (ja) | 2015-01-29 |
JP6482274B2 true JP6482274B2 (ja) | 2019-03-13 |
Family
ID=48534764
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014544045A Active JP6482274B2 (ja) | 2011-11-30 | 2012-11-28 | 皮膚バリア機能を改善するのに有用なホホバ抽出物 |
JP2017181977A Pending JP2018027965A (ja) | 2011-11-30 | 2017-09-22 | 皮膚バリア機能を改善するのに有用なホホバ抽出物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017181977A Pending JP2018027965A (ja) | 2011-11-30 | 2017-09-22 | 皮膚バリア機能を改善するのに有用なホホバ抽出物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9949918B2 (ja) |
EP (1) | EP2785322B1 (ja) |
JP (2) | JP6482274B2 (ja) |
KR (1) | KR102020691B1 (ja) |
CN (2) | CN103957884A (ja) |
AU (1) | AU2012345458B2 (ja) |
BR (1) | BR112014012858B1 (ja) |
ES (1) | ES2871250T3 (ja) |
HK (1) | HK1222802A1 (ja) |
WO (1) | WO2013080205A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015194054A1 (ja) * | 2014-06-20 | 2015-12-23 | 一丸ファルコス株式会社 | フェニルエチルアミン誘導体又はシネフリン含有デスモプラキン発現誘導剤又はデスモプラキン細胞膜局在誘導剤 |
US10202497B2 (en) * | 2015-09-10 | 2019-02-12 | Bridgestone Corporation | Microwave extraction technique for rubber and resin analysis |
CN107929101B (zh) * | 2017-11-17 | 2021-03-26 | 泰合玺健康科技南京有限公司 | 紧致按摩精油及其制作方法 |
KR102309616B1 (ko) * | 2021-07-27 | 2021-10-05 | 최금실 | 호호바오일을 포함하는 피부 재생 및 피부 보습용 화장료 조성물 및 이의 제조방법 |
WO2023217936A1 (en) * | 2022-05-11 | 2023-11-16 | Dsm Ip Assets B.V. | Novel use of a blend of sugars comprising psicose, mannose, fructose and glucose |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TNSN02063A1 (en) | 2001-07-07 | 2005-12-23 | Egyptian Natural Oil Co Natoil | The medical effect of jojoba oil |
JP2003034644A (ja) | 2001-07-17 | 2003-02-07 | Koei Kogyo Kk | ヒアロニダーゼ阻害剤及び皮膚外用組成物 |
US20030091665A1 (en) | 2001-11-09 | 2003-05-15 | Avon Products, Inc | Topical cosmetic composition with skin rejuvenation benefits |
JP4828077B2 (ja) * | 2002-03-19 | 2011-11-30 | 株式会社ディーエイチシー | 皮膚外用剤 |
US7155273B2 (en) * | 2002-07-29 | 2006-12-26 | Taylor Geoffrey L | Blanching response pressure sore detector apparatus and method |
US7025957B2 (en) | 2002-09-06 | 2006-04-11 | Desert Whale Jojoba Company | Composition and method to whiten skin |
US6890566B2 (en) | 2002-12-11 | 2005-05-10 | Desert Whale Jojoba Company | Composition and method to whiten and exfoliate skin |
US20040265249A1 (en) * | 2003-06-24 | 2004-12-30 | Desert Whale Jojoba Company | Composition for protecting skin from damaging effects of ultraviolet light |
KR101352363B1 (ko) | 2007-02-28 | 2014-02-05 | (주)아모레퍼시픽 | 현삼추출물을 유효성분으로 함유하는 피부 보습용 외용제조성물 |
EP2124868A4 (en) | 2007-03-29 | 2014-06-11 | Int Flora Technologies Ltd | TREATMENT OF SYMPTOMS OF DERMATOSIS AFFECTING A MAMMALIAN TEGUMENT WITH EMOLLIENT DISINFECTANT FORMULATIONS |
JP5207664B2 (ja) | 2007-06-04 | 2013-06-12 | 株式会社シャネル化粧品技術開発研究所 | 化粧品 |
KR101480700B1 (ko) | 2007-11-30 | 2015-01-12 | (주)아모레퍼시픽 | 복방 생약 추출물을 유효성분으로 함유하는 피부 외용제조성물 |
WO2009106934A1 (en) | 2008-02-29 | 2009-09-03 | Chemyunion Química Ltda | Angico-branco (piptadenia colubrina) extracts for use in cosmetic and dermatological formulations |
-
2012
- 2012-11-28 WO PCT/IL2012/050484 patent/WO2013080205A1/en active Application Filing
- 2012-11-28 KR KR1020147016905A patent/KR102020691B1/ko active IP Right Grant
- 2012-11-28 CN CN201280059319.0A patent/CN103957884A/zh active Pending
- 2012-11-28 BR BR112014012858-8A patent/BR112014012858B1/pt not_active IP Right Cessation
- 2012-11-28 CN CN201610028168.2A patent/CN105708870A/zh active Pending
- 2012-11-28 US US14/361,701 patent/US9949918B2/en active Active
- 2012-11-28 EP EP12853071.4A patent/EP2785322B1/en active Active
- 2012-11-28 AU AU2012345458A patent/AU2012345458B2/en not_active Ceased
- 2012-11-28 ES ES12853071T patent/ES2871250T3/es active Active
- 2012-11-28 JP JP2014544045A patent/JP6482274B2/ja active Active
-
2016
- 2016-09-21 HK HK16111062.2A patent/HK1222802A1/zh unknown
-
2017
- 2017-09-22 JP JP2017181977A patent/JP2018027965A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1222802A1 (zh) | 2017-07-14 |
KR20140098806A (ko) | 2014-08-08 |
AU2012345458B2 (en) | 2017-07-27 |
JP2018027965A (ja) | 2018-02-22 |
BR112014012858A2 (pt) | 2017-06-13 |
WO2013080205A1 (en) | 2013-06-06 |
AU2012345458A1 (en) | 2014-06-19 |
ES2871250T3 (es) | 2021-10-28 |
US9949918B2 (en) | 2018-04-24 |
CN103957884A (zh) | 2014-07-30 |
EP2785322B1 (en) | 2021-03-10 |
EP2785322A1 (en) | 2014-10-08 |
CN105708870A (zh) | 2016-06-29 |
EP2785322A4 (en) | 2015-05-27 |
BR112014012858B1 (pt) | 2019-02-26 |
US20140308372A1 (en) | 2014-10-16 |
KR102020691B1 (ko) | 2019-09-10 |
JP2015502942A (ja) | 2015-01-29 |
WO2013080205A8 (en) | 2014-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018027965A (ja) | 皮膚バリア機能を改善するのに有用なホホバ抽出物 | |
TWI381834B (zh) | Abnormal protein removal composition | |
US11285093B2 (en) | Cosmetic uses of swertiamarin | |
US20130310540A1 (en) | Extract of aquatic animal cartilage | |
TW201206495A (en) | Compositions and methods for stimulating MAGP-1 to improve the appearance of skin | |
TW200812638A (en) | Compositions comprising kakadu plum extract or acai berry extract | |
KR102315208B1 (ko) | 폴리고눔 비스토르타 추출물의 미용 또는 피부과 용도 | |
CN1694716A (zh) | 利用活性提取物改善皮肤、嘴唇、毛发和/或指甲的外观 | |
KR101453610B1 (ko) | 제니포사이드를 유효성분으로 포함하는 피부 주름 개선 또는 피부 탄력 증진용 화장료 조성물 | |
US20040043047A1 (en) | Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells | |
CN111148506A (zh) | 在化妆品和/或营养保健品中使用Let-7b抑制剂的方法 | |
EP3043873A1 (fr) | Utilisation cosmetique ou dermatologique d'un extrait de tapirira guyanensis | |
KR20160000318A (ko) | 전나무 오일을 포함하는 화장료 조성물 | |
TWI352602B (en) | Use of active extracts to improve the appearance o | |
KR101452582B1 (ko) | 테트라하이드로팔마틴을 유효성분으로 포함하는 피부 주름 개선 또는 피부 탄력 증진용 화장료 조성물 | |
KR101910865B1 (ko) | 발아 인삼씨 추출물을 함유하는 피부 외용제 조성물 | |
Marimuthu et al. | Effects of Oral supplementation of trichovitalsTM on human skin, hair and Nail physiology | |
KR20170035658A (ko) | 크립토클로로겐산을 유효성분으로 포함하는 피부 개선용 조성물 | |
KR20210027182A (ko) | 섬나리 추출물을 포함하는 조성물 | |
EP2785314B1 (fr) | Composition topique comprenant une association d'au moins un extrait d'algue bleue avec au moins un acide alpha hydroxyle ou un de ses sels | |
KR101434034B1 (ko) | 홀시틴을 유효성분으로 포함하는 피부 개선 또는 피부 탄력 증진용 화장료 조성물 | |
TW202007407A (zh) | 白芷發酵物及其製備方法與用於改善皮膚外觀的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151102 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170221 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170922 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171108 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20171222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181217 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6482274 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |